Posted by Michael Wonder on 29 Jul 2025
FDA approves Skytrofa (lonapegsomatropin-tcgd) for the once weekly treatment of adults with growth hormone deficiency
28 July 2025 - On track to initiate basket trial for idiopathic short stature, SHOX deficiency, Turner syndrome, and short for gestational age, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4, 2025
Ascendis Pharma today announced that the US FDA has approved Skytrofa (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency, a rare disorder resulting from decreased or total loss of growth hormone production.
